Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Legacy of Amyloid: Infiltration Linked to Dementia, Rheumatic Disease

Simon M. Helfgott, MD  |  Issue: October 2017  |  October 16, 2017

Aβ plaques act primarily as a trigger of other downstream processes, particularly tau aggregation, which mediate neurodegeneration. The major pathogenic effects of Aβ plaques may occur very early in the disease process.7 There may be little benefit in attacking these plaques later in their development. This suspicion has been confirmed by the disappointing results of several clinical trials.8 Targeting critical enzyme inhibitors of plaque formation has failed, too, and a trial using aggregated human Aβ as a therapeutic agent was halted when some participants developed an autoimmune encephalopathy.9 It may be time to abandon the amyloid hypothesis and seek a better explanation for the neuronal destruction caused by AD.

An Unrelenting Adversary or An Unanticipated Ally?

Unfortunately, the deposition of amyloid in any tissue, especially the brain, never relents. The high prevalence of AD has affected countless families as it progressively destroys the brains of some of our loved ones. But it is a condition that is not limited to the aged.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

More recently, the term chronic traumatic encephalopathy (CTE) has been applied when the neuropathology findings of boxer’s brain were observed in retired professional football and hockey players, entertainment wrestlers, victims of domestic violence and military veterans exposed to blast and concussive injuries from improvised explosive devices. The cognitive and behavioral symptoms of CTE begin insidiously; first, there may be mood changes such as depression, apathy and irritability, which sadly may end in suicide.11 CTE is characterized by prominent deposition of tau and variable degrees of diffuse amyloid deposition, although the areas of brain involvement seem to differ from what is seen in AD.

Could there be any benefit to amyloid’s presence in our bodies? There may be a silver lining. Unlike other human biological fluids, healthy semen contains multiple types of amyloid fibrils. In a recent study, it was noted that these fibrils inhibited fertilization by immobilizing sperm.12 Interestingly, this immobilization facilitated the uptake and clearance of sperm by macrophages, which are known to infiltrate the female reproductive tract following semen exposure. In the presence of semen fibrils, damaged and apoptotic sperm were more rapidly phagocytosed than healthy ones, suggesting that the deposition of semen fibrils in the female reproductive tract facilitates the clearance of poor-quality sperm.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

It’s heartening to learn that nature has found a way to put this pernicious protein to proper use somewhere in our bodies. Who knew? Amyloid as sperm selector; amyloid as our ally.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:Amyloidosisbraincase reportClinicaldementiaDiagnosismortalityneuronoutcomepatient careplaquerheumatologistrheumatology

Related Articles

    What Rheumatologists Need to Know about Identifying Amyloidosis

    June 1, 2013

    Although amyloidosis is not a rheumatic disease, rheumatologists may be the first to diagnose this life-threatening condition

    An Amylodosis Warning & New Drug Hope

    March 17, 2018

    SAN DIEGO—Treatments do exist that can improve the prospects of a patient with the rare disease amyloidosis, but only if clinicians keep the disease in mind and treat the patient before it’s too late, an expert said at the 2017 ACR/ARHP Annual Meeting this past November. He also discussed research that may be close to…

    Case Report: Does a Rapid-Onset Neck Mass Have Rheumatic Origins?

    September 17, 2019

    A 54-year-old African American man arrived at the emergency department with the acute onset of a tender mass on the left side of his neck. It had been getting progressively larger for the preceding two days. History & Examination His history included chronic right hip osteoarthritis with two surgeries performed five years prior. At his…

    Amyloidosis Is Often Underdiagnosed, Undertreated

    July 14, 2017

    CHICAGO—Caryn A. Libbey, MD, clinical associate professor of medicine at Boston University School of Medicine, described the evolving in our understanding of amyloid at the ACR’s State-of-the-Art Clinical Symposium in April. Amyloidosis is a rare disease that is often underdiagnosed and undertreated. “Even though this disease has been around for 150 years, I still consider it…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences